Peter Hjelmström joins UMC as new director

Communications / 06 March 2023

Uppsala Monitoring Centre (UMC), the WHO Collaborating Centre for International Drug Monitoring, is pleased to announce the arrival of its new director Peter Hjelmström.

AFTER MORE THAN 25 YEARS of experience within academia, healthcare, and the pharmaceutical industry, Peter Hjelmström brings with him a broad insight into the role of pharmacovigilance and patient safety.

Hjelmström has an academic background as a physician and scientist, with MD and PhD degrees. He was an associate professor at Karolinska Institutet before joining the pharmaceutical industry where he has worked in various roles. He did his postdoctoral fellowship at Yale University.

He singles out UMC’s heritage as a scientific leader, instrumental in building the field of pharmacovigilance, as being a key consideration in his decision to join UMC.

“It is a special organisation to be part of. It has achieved so much and has played a really important role in advancing patient safety globally since its foundation in 1978. That heritage, backed by the growing global member network of the WHO Programme for International Drug Monitoring and reinforced by continuous development of vital pharmacovigilance tools and services, together constitute a formidable platform for advancing medicine safety in the future and I am proud to now be a part of this organisation.”

UMC is a strong organisation with a great history, and we believe Peter’s leadership abilities are an excellent match for UMC’s future development.
Peter Hjelmström and UMC Board Chair, Filippa Nyberg

Peter Hjelmström and UMC Board Chair, Filippa Nyberg

Speaking on behalf of the UMC Board, Chair Filippa Nyberg said: “We are very pleased that Peter accepted to become the next director of UMC. With his clinical and scientific background, extensive industry experience and focus on patient safety, Peter brings a rare skillset to the role. UMC is a strong organisation with a great history, and we believe Peter’s leadership abilities are an excellent match for UMC’s future development.”

You may also like

Patient voices in pharmacovigilance takes centre stage at ISoP Bali 2023

The most recent ISoP event saw hundreds of experts gather to explore the latest innovations and challenges facing pharmacovigilance, with a special focus on patient perspectives.

Communications / 16 January 2024

Patient safety set to gain from new partnership between CDISC and UMC

The partnership seeks to improve the interoperability of CDISC standards and WHODrug Global for more effective sharing and use of medicinal product safety data.

Communications / 20 February 2024

When drugs damage the liver– New podcast out now

The liver, responsible for drug metabolism in the body, is also most at risk of damage due to medicines. Unravel the complexities of DILI and its impact on medication safety.

Communications / 05 February 2024

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more